R-Bendamustine for relapsed marginal zone lymphoma (post-rituximab failure)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-RITUXIMAB` `DRUG-BENDAMUSTINE`

ID	`REG-R-BENDAMUSTINE-RELAPSED-MZL`
Type	Regimen
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-MZL-2024` `SRC-NCCN-BCELL-2025`

Notes

Standard 2L for SMZL/NMZL after rituximab monotherapy failure. ORR ~85-90%; median PFS ~3-4 years. PJP prophylaxis ≥6 mo post-anti-CD20; HBV reactivation surveillance mandatory.

Used By

Indication

IND-NMZL-2L-BR - IND-NMZL-2L-BR
IND-SMZL-2L-BR - IND-SMZL-2L-BR